Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Gains from Investment Securities (2020 - 2023)

SELLAS Life Sciences (SLS) has disclosed Gains from Investment Securities for 7 consecutive years, with $31000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Investment Securities rose 106.9% to $31000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $31000.0, a N/A change, with the full-year FY2024 number at $64000.0, up 106.45% from a year prior.
  • Gains from Investment Securities was $31000.0 for Q4 2023 at SELLAS Life Sciences, up from -$449000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $853000.0 in Q2 2020 to a low of -$449000.0 in Q4 2022.
  • A 4-year average of $167666.7 and a median of $77000.0 in 2020 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 106.9% in 2023; the steepest drop was 106.9% in 2023.
  • SELLAS Life Sciences' Gains from Investment Securities stood at -$1000.0 in 2019, then surged by 85400.0% to $853000.0 in 2020, then plummeted by 152.64% to -$449000.0 in 2022, then soared by 106.9% to $31000.0 in 2023.
  • Per Business Quant, the three most recent readings for SLS's Gains from Investment Securities are $31000.0 (Q4 2023), -$449000.0 (Q4 2022), and $449000.0 (Q1 2022).